Drug intelligence / Profile preview

H102

Development stage: Preclinical
Modality: Peptides, Small Molecules
Administration: Intranasal

Overview

"H102" is a non-specific identifier that refers to several distinct entities across different scientific and medical contexts. In a pharmaceutical context, it has been used to denote a potent small-molecule covalent inhibitor of SARS-CoV-2 main protease (Mpro) with strong anti-SARS-CoV-2 activity, and also a β-sheet breaker peptide investigated for its therapeutic potential in Alzheimer's disease. Additionally, "H102" identifies an ultrasound transducer used in studies of peripheral nerve stimulation.

Targets

Amyloid-beta aggregate (N-terminal epitope)Mpro (3C-like proteinase of SARS-CoV-2)

Beyond the preview

Go deeper on H102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H102.

Explore the full profile